Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clyraguard is a topical hospital-grade disinfectant spray developed by Clyra Medical Technologies for decontamination of personal protective equipment, especially face masks and coverings, to reduce cross-contamination risk from pathogens including SARS-CoV-2. The product is based on a proprietary copper-iodine small molecule mineral-based formulation derived from Clyra Medical's wound care technology and is designed to deliver broad-spectrum antimicrobial activity against viruses, bacteria, and fungi. It is described as alcohol-free, non-toxic, non-irritating, safe for skin contact, and capable of being sprayed directly onto masks while worn, functioning through direct microbicidal disinfection rather than a conventional receptor-targeted pharmacologic mechanism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Clyraguard.